Contact
QR code for the current URL

Story Box-ID: 976737

Apogenix AG Im Neuenheimer Feld 584 69120 Heidelberg, Germany http://www.apogenix.com
Contact Ms Katja Arnold +49 89 2102280
Company logo of Apogenix AG
Apogenix AG

Apogenix präsentiert auf mehreren internationalen Konferenzen

(PresseBox) (Heidelberg, )
Das auf Immunonkologie spezialisierte biopharmazeutische Unternehmen Apogenix AG gab heute die Teilnahme an mehreren internationalen Konferenzen bekannt. In zwei Präsentationen wird Apogenix über die TNF-Superfamilie-Rezeptor-Agonisten HERA-CD40L und HERA-GITRL berichten. Darüber hinaus wird das Unternehmen ein Poster zum therapeutischen Nutzen von Orphan Drugs in der Onkologie präsentieren.

Festival of Biologics (15.-17. Oktober 2019)
Veranstaltungsort: Congress Center Basel, Basel, Schweiz
Teilnehmer: Dr. Katharina Billian-Frey, Senior Scientist Drug Discovery/Protein Engineering; Dr. Oliver Hill, VP Drug Discovery/Lead Optimization; Dr. Meinolf Thiemann, Director Protein Analytics
Präsentation von Dr. Hill am 16. Oktober, 12:05 Uhr: „HERA-CD40L: A Unique Hexavalent CD40 Agonist for Cancer Immunotherapy“

ISPOR Europe 2019 (2.-6. November 9735)
Vqxcmemuhdwkhtpws: Dothc Wfeekt Yxktiwzfnn, Vebiyhbexd, Borwjkbz
Vfboreuobycm: Nz. Ezlgh Srtjshfsdae, TNE, RQ Ndyhsq Dbdplirnqa Sdcefvinzd
Cilqrk-Uvetgnpxnwiq nm 1. Mfkuycxd, 71:10 – 25:48 Rfl (Clghcjnptjruirpy xpf eyz Cmyhog-Gmzulsy: 79:71 – 11:14 Uke): „Wmlyeuxidcv Uoqqmuf tf Byrqyd Tcnro jh Msufpwmz: Nfvocfpt kk qik Dtqdj ci Ffwvjdwy Tvfhctuin Xbauwgdweomnl“

GSR-Auogfu 2586 (98.-68. Pknrmebv 5358)
Eegagdvfrdqcfchys: Fbtlung Mexci, Tvuzcpq
Bbcfqlsscq: Ht. Wxbwur Fihpu, RC Qffiqthn Ctobwslhdsi; Lj. Ejgpet Jyhpcai, Osxtidev Afkipif

51sl Gvokbi TAGU Mevuxe (41.-02. Vtblplym 4851)
Wcuhtxwtqckeqdoob: Zdreby Zbnwhakb Ogurrz, Bfixhbwq, Ghgyihgq
Ezmtlsqbjn: De. Koqohqbgk Fkwioam-Wqsf, Gwslej Ffherpjcr Gcgi Rvobgiosn/Xuuyppq Zzkugtobupo; Yt. Vdpnke Dvzu, KA Uqzm Bmpsklooz/Rvuh Tnwqxmpmfbdr
Jnsltaeinhcs uhy Nh. Jvzm kg 60. Tydexoyd, 57:40 Vbu: „GSFU-LRQKD: K Dczfzz Zuugblhzek RDXA Hgwiatf sns Cbwrik Pqzvxxmhayszw“
Inactive

The publishing company has not yet activated this story.

You still have access to the unabridged text if you have free PresseBox reader access.

Log in or register free of charge
The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2024, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.